23.10.2024 • NewsAvantiuminvestment

Avantium Opens Biobased FDCA Plant in the Netherlands

Dutch renewables specialist Avantium has officially opened its FDCA (furandicarboxylic acid) flagship plant in Delfzijl, the Netherlands. Plans for what was said to be the world's first commercial-scale production plant for FDCA were first announced in December 2021.

In the plant, Avantium will produce 5,000 t of FDCA, the essential building block for 100% plant-based and circular plastic PEF (polyethylene furanoate), known under the brand name Releaf. The company’s material has versatile applications including bottles, packaging, films, and textiles.

Tom van Aken, Avantium’s CEO, said: “Our new FDCA plant embodies our commitment to innovation and sustainability. We are excited to lead the way in producing Releaf, a material that offers a viable alternative to traditional petroleum-based plastics. This plant is not just a testament to our technological advancements but also to our dedication to creating long-term, sustainable value for all our stakeholders.”

Avantium also plans to accelerate the rollout of its FDCA/PEF licensing strategy.

© Avantium
© Avantium

Company

Logo:

Avantium

Zekeringstraat 29
1014 BV Amsterdam
Netherlands

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read